Clinical trials: Solid Tumors Refractory To Standard Therapy
Neoplasm Metastasis
Stem Cell Transplantation for Metastatic Solid Tumors
The goal of this research study is to identify other types of cancer (malignant neoplasms) that may be treatable with stem cell transplantation (allogenic peripheral blood stem cell transplantation.
- Trial name
- NCT00001880
- Testing
- methotrexate, Cyclosporin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00027898
- Testing
- bortezomib, carboplatin, etoposide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Advanced Cancers, Solid Tumors
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer.
- Trial name
- NCT01430572
- Testing
- Pazopanib, Everolimus
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center